We have the potential to end the HIV epidemic. But why hasn’t it happened yet?

We have the potential to end the HIV epidemic. But why hasn’t it happened yet?
Researchers are increasingly interested in how a systems biology approach may be used to tackle multi-scale heart problems.
An artificial cell, which uses a microfluidics-based approach to engineer a modular and programable artificial‐cell‐on‐chip.
Scientists take us a step closer to making cell transplantation a viable clinical option.
Gilbert X. Gonzalez tells how his lab are working on influenza vaccines that can overcome the problems of the seasonal influenza vaccine.
Inactivating viruses from biopharmaceutical source materials can be achieved with detergents. However, the frequently used detergent Triton X-100 is ecotoxic and must be replaced with eco-friendly alternatives.
In 2019, CRISPR gene-editing therapy was used for the first time to treat sickle cell disease.
Protein-protected metal nanoclusters have excellent biocompatibility and have received considerable attention as a luminescent probe in a number of fields such as biosensing, bioimaging, and imaging-guided therapy.
“This work opens new avenues for material scientists and biologists to mimic in the lab the structure of living tissues and to upscale the production of engineered constructs.” ~ Dr. Riccardo Levato and Prof. Chris Moser.
Pharmacists‐led interventions can significantly reduce medical risk factors, supporting the involvement of pharmacists as healthcare providers in managing patients with hypertension, diabetes and dyslipidaemia.